Literature DB >> 16862522

Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation.

Steve Kitchen1, Ion Jennings, Tim A L Woods, Dianne P Kitchen, Isobel D Walker, Francis E Preston.   

Abstract

In recognition of the importance of von Willebrand factor (vWF) testing in the diagnosis of von Willebrand disease (vWD), the United Kingdom National External Quality Assessment Scheme for Blood Coagulation regularly distributes samples for determination of vWF:antigen (vWF:Ag). Data from 10 separate surveys performed between 2001 and 2005 are reviewed. These include results from ~200 different centers, of which 55% are within the United Kingdom and the remainder are from other countries. During the period of the surveys, the use of immunoelectrophoresis for determination of vWF:Ag practically disappeared and was largely replaced by latex agglutination assays. The coefficient of variation (CV) of results in different centers was approximately 15 to 20% for most vWF:Ag techniques, with CVs of approximately 7% for a fluorescence-based assay. Several different techniques were used for determination of vWF ristocetin cofactor activity (vWF:RCo), all of which were associated with poor agreement among centers as indicated by CVs of 40 to 50%. Several centers calculated the ratio of vWF:Ag/vWF:RCo but with variable success. Ratios compatible with either type 1 or type 2 vWD were obtained on samples from subjects with type 1 vWD, as well as on samples from subjects with genetically confirmed type 2 vWD. Overall, our data show that laboratory testing for vWD remains problematic. It remains to be seen whether newer techniques will offer consistently improved precision.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16862522     DOI: 10.1055/s-2006-947863

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  28 in total

1.  Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.

Authors:  Veronica H Flood; Pamela A Christopherson; Joan Cox Gill; Kenneth D Friedman; Sandra L Haberichter; Daniel B Bellissimo; Rupa A Udani; Mahua Dasgupta; Raymond G Hoffmann; Margaret V Ragni; Amy D Shapiro; Jeanne M Lusher; Steven R Lentz; Thomas C Abshire; Cindy Leissinger; W Keith Hoots; Marilyn J Manco-Johnson; Ralph A Gruppo; Lisa N Boggio; Kate T Montgomery; Anne C Goodeve; Paula D James; David Lillicrap; Ian R Peake; Robert R Montgomery
Journal:  Blood       Date:  2016-02-09       Impact factor: 22.113

2.  Rapid discrimination of the phenotypic variants of von Willebrand disease.

Authors:  Jonathan C Roberts; Patti A Morateck; Pamela A Christopherson; Ke Yan; Raymond G Hoffmann; Joan Cox Gill; Robert R Montgomery
Journal:  Blood       Date:  2016-02-25       Impact factor: 22.113

Review 3.  Advances in the diagnosis and treatment of Von Willebrand disease.

Authors:  Ruchika Sharma; Veronica H Flood
Journal:  Blood       Date:  2017-11-30       Impact factor: 22.113

4.  Hypertrophic obstructive cardiomyopathy, acquired von Willebrand syndrome, and gastrointestinal bleeding.

Authors:  Rajiv K Pruthi
Journal:  Mayo Clin Proc       Date:  2011-03       Impact factor: 7.616

Review 5.  Laboratory aspects of von Willebrand disease: test repertoire and options for activity assays and genetic analysis.

Authors:  G Castaman; A Hillarp; A Goodeve
Journal:  Haemophilia       Date:  2014-05       Impact factor: 4.287

Review 6.  Diagnostic approach to von Willebrand disease.

Authors:  Christopher Ng; David G Motto; Jorge Di Paola
Journal:  Blood       Date:  2015-02-23       Impact factor: 22.113

7.  The role of genetics in the pathogenesis and diagnosis of type 1 Von Willebrand disease.

Authors:  Veronica H Flood; Jessica Garcia; Sandra L Haberichter
Journal:  Curr Opin Hematol       Date:  2019-09       Impact factor: 3.284

Review 8.  Laboratory diagnosis of von Willebrand disease.

Authors:  J C Roberts; V H Flood
Journal:  Int J Lab Hematol       Date:  2015-05       Impact factor: 2.877

9.  Von Willebrand disease in the United States: perspective from the Zimmerman program.

Authors:  Veronica H Flood; Thomas C Abshire; Pamela A Christopherson; Kenneth D Friedman; Joan Cox Gill; Robert R Montgomery; Sandra L Haberichter
Journal:  Ann Blood       Date:  2018-01-26

10.  No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation.

Authors:  Veronica H Flood; Kenneth D Friedman; Joan Cox Gill; Sandra L Haberichter; Pamela A Christopherson; Brian R Branchford; Raymond G Hoffmann; Thomas C Abshire; Amy L Dunn; Jorge A Di Paola; W Keith Hoots; Deborah L Brown; Cindy Leissinger; Jeanne M Lusher; Margaret V Ragni; Amy D Shapiro; Robert R Montgomery
Journal:  Blood       Date:  2013-03-21       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.